{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:33:46Z","timestamp":1792787626339,"version":"4.5.0"},"reference-count":84,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":103,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["U54 CA224018"],"award-info":[{"award-number":["U54 CA224018"]}]},{"name":"National Cancer Institute","award":["P50 CA186781"],"award-info":[{"award-number":["P50 CA186781"]}]},{"name":"National Cancer Institute","award":["R01 CA192844-04S1"],"award-info":[{"award-number":["R01 CA192844-04S1"]}]},{"name":"National Cancer Institute","award":["K22 CA266739"],"award-info":[{"award-number":["K22 CA266739"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Multiple myeloma (MM) is a malignancy that is often driven by MYC and that is sustained by IRF4, which are upregulated by super-enhancers. IKZF1 and IKZF3 bind to super-enhancers and can be degraded using immunomodulatory imide drugs (IMiD). Successful IMiD responses downregulate MYC and IRF4; however, this fails in IMiD-resistant cells. MYC and IRF4 downregulation can also be achieved in IMiD-resistant tumors using inhibitors of BET and EP300 transcriptional coactivator proteins; however, in vivo these drugs have a narrow therapeutic window. By combining IMiDs with EP300 inhibition, we demonstrate greater downregulation of MYC and IRF4, synergistic killing of myeloma in vitro and in vivo, and an increased therapeutic window. Interestingly, this potent combination failed where MYC and IRF4 expression was maintained by high levels of the AP-1 factor BATF. Our results identify an effective drug combination and a previously unrecognized mechanism of IMiD resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>These results highlight the dependence of MM on IKZF1-bound super-enhancers, which can be effectively targeted by a potent therapeutic combination pairing IMiD-mediated degradation of IKZF1 and IKZF3 with EP300 inhibition. They also identify AP-1 factors as an unrecognized mechanism of IMiD resistance in MM.<\/jats:p>\n                    <jats:p>See related article by Neri, Barwick, et al., p. 56.<\/jats:p>\n                    <jats:p>See related commentary by Yun and Cleveland, p. 5.<\/jats:p>\n                    <jats:p>This article is featured in Selected Articles from This Issue, p. 4<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0062","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:33:22Z","timestamp":1695879202000},"page":"34-55","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-2162","authenticated-orcid":false,"given":"Seth J.","family":"Welsh","sequence":"first","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9709-7624","authenticated-orcid":false,"given":"Erin W.","family":"Meermeier","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-2027","authenticated-orcid":false,"given":"Daniel L.","family":"Riggs","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7093-2004","authenticated-orcid":false,"given":"Chang-Xin","family":"Shi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-7756","authenticated-orcid":false,"given":"Yuan Xiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3128-4517","authenticated-orcid":false,"given":"Meaghen E.","family":"Sharik","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0486-4837","authenticated-orcid":false,"given":"Megan T.","family":"Du","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8219-9238","authenticated-orcid":false,"given":"Leslie D.","family":"Abrego Rocha","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0535-6508","authenticated-orcid":false,"given":"Victoria M.","family":"Garbitt","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9561-140X","authenticated-orcid":false,"given":"Caleb K.","family":"Stein","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6717-1976","authenticated-orcid":false,"given":"Joachim L.","family":"Petit","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9281-7776","authenticated-orcid":false,"given":"Nathalie","family":"Meurice","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2626-1227","authenticated-orcid":false,"given":"Yuliza","family":"Tafoya Alvarado","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-0340","authenticated-orcid":false,"given":"Rodrigo","family":"Fonseca","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3966-7779","authenticated-orcid":false,"given":"Kennedi T.","family":"Todd","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7829-707X","authenticated-orcid":false,"given":"Sochilt","family":"Brown","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6383-1856","authenticated-orcid":false,"given":"Zachery J.","family":"Hammond","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1441-2415","authenticated-orcid":false,"given":"Nicklus H.","family":"Cuc","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5561-8136","authenticated-orcid":false,"given":"Courtney","family":"Wittenberg","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9329","authenticated-orcid":false,"given":"Camille","family":"Herzog","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6152-5439","authenticated-orcid":false,"given":"Anna V.","family":"Roschke","sequence":"additional","affiliation":[{"name":"3Genetics Branch, Center for Cancer Research, NCI, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7792-9109","authenticated-orcid":false,"given":"Yulia N.","family":"Demchenko","sequence":"additional","affiliation":[{"name":"3Genetics Branch, Center for Cancer Research, NCI, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-5515","authenticated-orcid":false,"given":"Wei-dong D.","family":"Chen","sequence":"additional","affiliation":[{"name":"3Genetics Branch, Center for Cancer Research, NCI, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4721-5936","authenticated-orcid":false,"given":"Peng","family":"Li","sequence":"additional","affiliation":[{"name":"4Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liao","sequence":"additional","affiliation":[{"name":"4Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-7448","authenticated-orcid":false,"given":"Warren J.","family":"Leonard","sequence":"additional","affiliation":[{"name":"4Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-9323","authenticated-orcid":false,"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada."},{"name":"6Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-3647","authenticated-orcid":false,"given":"Paola","family":"Neri","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada."},{"name":"6Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-8225","authenticated-orcid":false,"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"2024012514533958500_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"2024012514533958500_bib2","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"key":"2024012514533958500_bib3","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"key":"2024012514533958500_bib4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"key":"2024012514533958500_bib5","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012514533958500_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","article-title":"Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines","volume":"88","author":"Chesi","year":"1996","journal-title":"Blood"},{"key":"2024012514533958500_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2024012514533958500_bib8","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"2024012514533958500_bib9","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"key":"2024012514533958500_bib10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"2024012514533958500_bib11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni1357","article-title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination","volume":"7","author":"Klein","year":"2006","journal-title":"Nat Immunol"},{"key":"2024012514533958500_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"2024012514533958500_bib13","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","article-title":"The Tao of myeloma","volume":"124","author":"Boise","year":"2014","journal-title":"Blood"},{"key":"2024012514533958500_bib14","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"2024012514533958500_bib15","first-page":"11481","article-title":"Super-enhancers in transcriptional regulation and genome organization","volume":"47","author":"Wang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2024012514533958500_bib16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature14289","article-title":"Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice","volume":"521","author":"Adam","year":"2015","journal-title":"Nature"},{"key":"2024012514533958500_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.3167","article-title":"What are super-enhancers?","volume":"47","author":"Pott","year":"2015","journal-title":"Nat Genet"},{"key":"2024012514533958500_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"2024012514533958500_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"2024012514533958500_bib20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"2024012514533958500_bib21","doi-asserted-by":"crossref","first-page":"e10483","DOI":"10.7554\/eLife.10483","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma","volume":"5","author":"Conery","year":"2016","journal-title":"eLife"},{"key":"2024012514533958500_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"key":"2024012514533958500_bib23","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1021\/acs.jmedchem.7b00796","article-title":"GNE-781, A highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP)","volume":"60","author":"Romero","year":"2017","journal-title":"J Med Chem"},{"key":"2024012514533958500_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbpa.2018.06.005","article-title":"Modulating the masters: chemical tools to dissect CBP and p300 function","volume":"45","author":"Breen","year":"2018","journal-title":"Curr Opin Chem Biol"},{"key":"2024012514533958500_bib25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Vannam","year":"2021","journal-title":"Cell Chem Biol"},{"key":"2024012514533958500_bib26","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.molcel.2021.04.015","article-title":"Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300\/CBP inhibition","volume":"81","author":"Hogg","year":"2021","journal-title":"Mol Cell"},{"key":"2024012514533958500_bib27","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.celrep.2018.07.041","article-title":"Enhancer activity requires CBP\/P300 bromodomain-dependent histone H3K27 acetylation","volume":"24","author":"Raisner","year":"2018","journal-title":"Cell Rep"},{"key":"2024012514533958500_bib28","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol"},{"key":"2024012514533958500_bib29","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br J Cancer"},{"key":"2024012514533958500_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"2024012514533958500_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"2024012514533958500_bib32","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1038\/s41375-019-0474-0","article-title":"Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity","volume":"33","author":"Ding","year":"2019","journal-title":"Leukemia"},{"key":"2024012514533958500_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J"},{"key":"2024012514533958500_bib34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1084\/jem.20031571","article-title":"Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity","volume":"199","author":"Cort\u00e9s","year":"2004","journal-title":"J Exp Med"},{"key":"2024012514533958500_bib35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12185-014-1644-5","article-title":"Ikaros fingers on lymphocyte differentiation","volume":"100","author":"Yoshida","year":"2014","journal-title":"Int J Hematol"},{"key":"2024012514533958500_bib36","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1101\/gad.283762.116","article-title":"Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia","volume":"30","author":"Hu","year":"2016","journal-title":"Genes Dev"},{"key":"2024012514533958500_bib37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"2024012514533958500_bib38","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"key":"2024012514533958500_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/10428194.2018.1466290","article-title":"Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma","volume":"60","author":"Dimopoulos","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2024012514533958500_bib40","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"key":"2024012514533958500_bib41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s43018-023-00550-x","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","author":"De Matos Simoes","year":"2023","journal-title":"Nat Cancer"},{"key":"2024012514533958500_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"2024012514533958500_bib43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"2024012514533958500_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.021","article-title":"Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer","volume":"394","author":"Leal","year":"2017","journal-title":"Cancer Lett"},{"key":"2024012514533958500_bib45","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"23:S1535\u20136108","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"},{"key":"2024012514533958500_bib46","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1182\/blood-2019-124707","article-title":"CCS1477: a novel small molecule inhibitor of p300\/CBP bromodomain for the treatment of acute myeloid leukaemia and multiple myeloma","volume":"134","author":"Brooks","year":"2019","journal-title":"Blood"},{"key":"2024012514533958500_bib47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov"},{"key":"2024012514533958500_bib48","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2024012514533958500_bib49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2024012514533958500_bib50","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-021-01025-w","article-title":"OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity","volume":"22","author":"Doane","year":"2021","journal-title":"Nat Immunol"},{"key":"2024012514533958500_bib51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature11530","article-title":"BATF-JUN is critical for IRF4-mediated transcription in T cells","volume":"490","author":"Li","year":"2012","journal-title":"Nature"},{"key":"2024012514533958500_bib52","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1182\/blood.V122.21.1914.1914","article-title":"The comprehensive genomic characterization of all commercially and non-commercially available multiple myeloma cell lines","volume":"122","author":"Yellapantula","year":"2013","journal-title":"Blood"},{"key":"2024012514533958500_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/med.21575","article-title":"ETS transcription factors as emerging drug targets in cancer","volume":"40","author":"Hsing","year":"2020","journal-title":"Med Res Rev"},{"key":"2024012514533958500_bib54","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/cancers13102326","article-title":"The role of AP-1 transcription factors in plasma cell biology and multiple myeloma pathophysiology","volume":"13","author":"Fan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024012514533958500_bib55","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2024012514533958500_bib56","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"2024012514533958500_bib57","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41375-020-01078-0","article-title":"The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival","volume":"35","author":"Fedele","year":"2021","journal-title":"Leukemia"},{"key":"2024012514533958500_bib58","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1126\/science.1228309","article-title":"A genomic regulatory element that directs assembly and function of immune-specific AP-1 - IRF complexes","volume":"338","author":"Glasmacher","year":"2012","journal-title":"Science"},{"key":"2024012514533958500_bib59","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11531","article-title":"Compensatory dendritic cell development mediated by BATF-IRF interactions","volume":"490","author":"Tussiwand","year":"2012","journal-title":"Nature"},{"key":"2024012514533958500_bib60","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"key":"2024012514533958500_bib61","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/ijms22031103","article-title":"Role of Aiolos and Ikaros in the antitumor and immunomodulatory activity of IMiDs in multiple myeloma: better to lose than to find them","volume":"22","author":"Cippitelli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024012514533958500_bib62","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"2024012514533958500_bib63","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1038\/s41375-021-01373-4","article-title":"Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs","volume":"35","author":"Jones","year":"2021","journal-title":"Leukemia"},{"key":"2024012514533958500_bib64","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","article-title":"Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity","volume":"132","author":"Sievers","year":"2018","journal-title":"Blood"},{"key":"2024012514533958500_bib65","doi-asserted-by":"crossref","first-page":"108532","DOI":"10.1016\/j.celrep.2020.108532","article-title":"Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins","volume":"34","author":"Shirasaki","year":"2021","journal-title":"Cell Rep"},{"key":"2024012514533958500_bib66","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41556-021-00766-y","article-title":"Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma","volume":"23","author":"Frede","year":"2021","journal-title":"Nat Cell Biol"},{"key":"2024012514533958500_bib67","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri3470","article-title":"Specificity through cooperation: BATF\u2013IRF interactions control immune-regulatory networks","volume":"13","author":"Murphy","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"2024012514533958500_bib68","doi-asserted-by":"crossref","first-page":"621093","DOI":"10.3389\/fphar.2020.621093","article-title":"Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials","volume":"11","author":"Sun","year":"2020","journal-title":"Front Pharmacol"},{"key":"2024012514533958500_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2024012514533958500_bib70","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonistssss induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"key":"2024012514533958500_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0320-7","article-title":"Direct to Drug\u201d screening as a precision medicine tool in multiple myeloma","volume":"10","author":"Bonolo de Campos","year":"2020","journal-title":"Blood Cancer J"},{"key":"2024012514533958500_bib72","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbr.2011.09.039","article-title":"Behavioral characterization of cereblon forebrain-specific conditional null mice: a model for human non-syndromic intellectual disability","volume":"226","author":"Rajadhyaksha","year":"2012","journal-title":"Behav Brain Res"},{"key":"2024012514533958500_bib73","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1158\/1078-0432.CCR-20-2931","article-title":"Chromatin accessibility identifies regulatory elements predictive of gene expression and disease outcome in multiple myeloma","volume":"27","author":"Barwick","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024012514533958500_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2024012514533958500_bib75","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2024012514533958500_bib76","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"key":"2024012514533958500_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2024012514533958500_bib78","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024012514533958500_bib79","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat Methods"},{"key":"2024012514533958500_bib80","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat Methods"},{"key":"2024012514533958500_bib81","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/nprot.2012.101","article-title":"Identifying ChIP-seq enrichment using MACS","volume":"7","author":"Feng","year":"2012","journal-title":"Nat Protoc"},{"key":"2024012514533958500_bib82","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.1038\/s41598-019-45839-z","article-title":"The ENCODE blacklist: identification of problematic regions of the genome","volume":"9","author":"Amemiya","year":"2019","journal-title":"Sci Rep"},{"key":"2024012514533958500_bib83","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41467-018-04234-4","article-title":"B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation","volume":"9","author":"Barwick","year":"2018","journal-title":"Nat Commun"},{"key":"2024012514533958500_bib84","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","article-title":"Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities","volume":"38","author":"Heinz","year":"2010","journal-title":"Mol Cell"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0062\/3367979\/bcd-23-0062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0062\/3389463\/bcd-23-0062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/1\/34\/3408473\/34.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/1\/34\/3408473\/34.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T09:58:21Z","timestamp":1706176701000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/1\/34\/732334\/Transcriptional-Heterogeneity-Overcomes-Super"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,27]]},"published-print":{"date-parts":[[2024,1,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0062","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.24958706.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958688.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958694.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062118","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958685.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958691.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062130.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062136.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062133.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958706","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958700.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958697","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958685","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958700","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062127","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958709.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062115","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958691","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062121","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062133","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062115.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958709","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062130","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958694","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062118.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958688","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.24958697.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062136","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062121.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062124.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062127.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.25062124","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7014119.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.7014119","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.7014119.v1","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}